Literature DB >> 20019983

The optimal management of T1 high-grade bladder cancer.

Kenneth G Nepple1, Michael A O'Donnell.   

Abstract

Stage T1Hg bladder cancer should be considered an aggressive and potentially lethal disease. The importance of initial re-resection to identify unrecognized muscle-invasive disease is significant. Most patients with high-risk disease are candidates for initial bladder salvage with intravesical bacillus Calmette-Guerin vaccine for immunotherapy, a procedure with a high survival rate; however, failure of the procedure may result in a guarded prognosis. Even after apparent success, patients should be informed of the risks of the disease progressing to muscle-invasive or metastatic disease and the need for vigilant monitoring. Despite optimal management, a significant number of patients relapse or progress to invasive disease requiring cystectomy. This review provides insight into the optimal management of T1 high-grade bladder cancer.

Entities:  

Year:  2009        PMID: 20019983      PMCID: PMC2792452     

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  61 in total

1.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

Authors:  Osama Shahin; George N Thalmann; Cyrill Rentsch; L Mazzucchelli; U E Studer
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  Treatment of superficial (T1) tumours of the bladder by radical radiotherapy.

Authors:  P M Quilty; W Duncan
Journal:  Br J Urol       Date:  1986-04

3.  Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.

Authors:  M Brake; H Loertzer; R Horsch; H Keller
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

4.  Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

Authors:  A Brauers; R Buettner; G Jakse
Journal:  J Urol       Date:  2001-03       Impact factor: 7.450

5.  Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.

Authors:  Stefan Denzinger; Wolfgang Otto; Hans-Martin Fritsche; Wolfgang Roessler; Wolf F Wieland; Arndt Hartmann; Maximilian Burger
Journal:  Int J Urol       Date:  2007-11       Impact factor: 3.369

6.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

7.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

8.  Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Authors:  Yair Lotan; Karim Bensalah; Timothy Ruddell; Shahrokh F Shariat; Arthur I Sagalowsky; Raheela Ashfaq
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

9.  Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.

Authors:  Tommaso Cai; Gabriella Nesi; Galliano Tinacci; Enzo Zini; Nicola Mondaini; Vieri Boddi; Sandra Mazzoli; Riccardo Bartoletti
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

Review 10.  Invasive T1 bladder cancer: indications and rationale for radical cystectomy.

Authors:  John P Stein; David F Penson
Journal:  BJU Int       Date:  2008-05-20       Impact factor: 5.588

View more
  13 in total

1.  Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system.

Authors:  Adam Kinnaird; Peter Dromparis; Howard Evans
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

2.  Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.

Authors:  Mohit Gupta; Niv Milbar; Giorgia Tema; Filippo Pederzoli; Meera Chappidi; Max Kates; Christopher J VandenBussche; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2019-01-23       Impact factor: 4.226

3.  A smoking cessation program as a resource for bladder cancer patients.

Authors:  Daniel Vilensky; Nathan Lawrentschuk; Karen Hersey; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2011-05-01       Impact factor: 1.862

Review 4.  Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.

Authors:  Ashish M Kamat; Thomas W Flaig; H Barton Grossman; Badrinath Konety; Donald Lamm; Michael A O'Donnell; Edward Uchio; Jason A Efstathiou; John A Taylor
Journal:  Nat Rev Urol       Date:  2015-03-24       Impact factor: 14.432

5.  p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis.

Authors:  Xiaofeng Zhou; Guan Zhang; Ye Tian
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 6.  Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis.

Authors:  Chenkui Miao; Chao Liang; Jundong Zhu; Aiming Xu; Kai Zhao; Yibo Hua; Jianzhong Zhang; Wei Chen; Chuanjian Suo; Chao Zhang; Yiyang Liu; Shifeng Su; Zengjun Wang
Journal:  Oncotarget       Date:  2017-05-09

7.  Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.

Authors:  Shunta Hori; Makito Miyake; Yoshihiro Tatsumi; Sayuri Onishi; Yosuke Morizawa; Yasushi Nakai; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

Review 8.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

9.  p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.

Authors:  Jun Du; Shu-hua Wang; Qing Yang; Qian-qian Chen; Xin Yao
Journal:  World J Surg Oncol       Date:  2016-04-30       Impact factor: 2.754

10.  Mechanism of hif-1α mediated hypoxia-induced permeability changes in bladder endothelial cells.

Authors:  C Liu; C L Shui; Q Wang; H Luo; C G Gu
Journal:  Braz J Med Biol Res       Date:  2017-12-18       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.